Genetic predictors for symptoms recurrenсe in coronary artery disease after percutaneous coronary intervention
Abstract
Genes of thrombosis and folate metabolism play an important role in development and progression of coronary artery disease (CAD). However, a possible role of polymorphic markers in CAD relapse following percutaneous coronary intervention (PCI) is not sufficiently understood. Background. Reports have indicated an association of genetic factors generally related with thrombophilia and recurrence of symptoms for coronary artery disease (CAD) following a percutaneous coronary intervention (PCI) due to restenosis and in-stent thrombosis. However, the relapse can also be caused by progression of atherosclerosis and endothelial dysfunction in unoperated blood vessels. Aim: To assess the role of genetic risk factors involved in thrombosis and folate metabolism (polymorphic markers of F5, F2, F13A1, PAI1, HPA1, MTHFR, and FGB genes) in recurrence of CAD symptoms after PCI. Methods: The study included 90 patients with CAD aged 40—75; 75 of these patients had undergone elective PCI (60 men and 15 women) and 15 patients — emergency PCI (12 men and 3 women). Molecular genetic tests were performed using a CVD StripAssays® reagent kit (ViennaLab Diagnostics GmbH, Austria) to identify the following genetic variations: F5, F2, F13A1, PAI1, HPA1, MTHFR, and FGB. Results: The study results showed a significant association of the G103T (Val34Leu) polymorphism in the F13A1 gene with relapses of IHD after PCI. Significant differences were found in genotype distribution frequencies of the Val34Leu polymorphism in the F13A1 gene. The frequency of Val/Val genotype was higher in patients with complications than without complications, 0.700 and 0.400, respectively (c2 = 7.78, p = 0.020). Furthermore, the Val/Val genotype can be classified as a risk factor for complications (OR = 3.50; 95% CI, 1.37—8.93). The L allele frequency was lower in patients with complications than in those without complications (0.167 and 0.375, respectively, p = 0.004), and carriage of the L allele reduced the likelihood of complications (OR = 0.33; 95% CI 0.15—0.72). Conclusion: Carriage of the 34V variant in the F13A1 gene that encodes the coagulation factor XIII A subunit predisposes to a relapse of CAD symptoms after PCI.
Downloads
References
2. Nikitin A.G., Chudakova D.A., Spitsina E.V. et al. Association of GNB3 gene C825T polymorphism with coronary heart disease. Genetika. 2007; 43 (8): 1129-33. (in Russian)
3. Kulikov I.V., Lozhkina N.G., Maksimov V.N. et al. Genetic markers of the severity of coronary artery in patients with acute coronary syndrome. Byulleten’ SO RАMN 2013, 33(4): 65-69. (in Russian)
4. Shesternja P.A., Nikulin S.Y., Shulman V.A. et al. Genetic predictors of myocardial infarction in subjects of young age. Kardiologiia. (Rus) 2013; 53 (7): 4-8. (in Russian)
5. The genetic passport — the basis of individual and predictive medicine / Ed. VS Baranov. — SPb.: Publishing house of the N-L, 2009. — 528 p.
6. Golubenko M.V., Stepanov V.A., Makeeva O.A. et al. DNA chip for the study of the structure of hereditary predisposition to cardiovascular disease. Molekuljarno- biologicheskie tehnologii v medicinskoj praktike 2009; 13: 42-49. (in Russian)
7. Sukhinina TS, Shakhnovich RM, Barsova RM et al. Value of allele gene polymorphism of the inflammation system for prognosis of patients with myocardial infarction. Kardiologiya. 2012; 52 (3):15-22. (in Russian)
8. Zykov M.V., Zykova D.S., Kashtalap V.V. et al. The prognostic value of peripheral arteries diseases in patients with ST-segment elevation myocardial infarction. Ateroskleroz. 2012; 8 (1): 14-21. (in Russian)
9. Pons D., Monraats P.S., de Maat M.P. et al. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost. 2007; 98(6):1323-28. doi.:10.1160/TH07-04-0301
10. Aslanabadi N., Monfaredan A., Niaei G. et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and restenosis events after coronary stent placement in Iranian Azari patients. Ulutas Gen Res J. 2016; 1(1): 11-17. doi: 10.5455/ugrj.20160210063642.
11. Zavalloni D., Presbitero P., Lodigiani C. et al. Prevalence of inherited thrombophilia in patients with documented stent thrombosis. Circ J. 2012; 76(8):1874-79. doi: 10.1253/circj.CJ-11-1358
12. Satra M., Samara M., Wozniak G. et al. Sequence variations in the FII, FV, F13A1, FGB and PAI-1 genes are associated with differences in myocardial perfusion. Pharmacogenomics. 2011; 12(2):195-203. doi: 10.2217/pgs.10.180.
13. Kufner S., Cassese S., Valeskini M. et al. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. JACC Cardiovasc Interv. 2015; 8(7):877-84. doi: 10.1016/j.jcin.2015.01.031.
14. Ortlepp JR., Hoffmann R., Killian A., Lauscher J., Merkelbach-Brese S., Hanrath P.The 4G/5G promotor polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol. 2001; 24(9):585-91.
15. Bоttiger C., Koch W., Lahn C., Mehilli J., von Beckerath N., Schоmig A., Kastrati A. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J. 2003; 146(5):855-61.
16. Katsaros K.M., Speidl W.S, Kastl SP, Zorn G., Huber K., Maurer G., Glogar D., Wojta J., Christ G. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost. 2008 Mar; 6(3):508-13. doi: 10.1111/j.1538-7836.2007.02884.x.
17. Gemmati D., Federici F, Campo G, Tognazzo S, Serino ML, De Mattei M, Valgimigli M, Malagutti P, Guardigli G, Ferraresi P, Bernardi F, Ferrari R, Scapoli GL, Catozzi L. Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients. Mol Med. 2007 Jan-Feb; 13(1-2):112-20.
18. Ariens R.A.S., Philippou H., Nagaswami C. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000; 96: 988-995.
19. Schroeder V., Chatterjee T., Kohler H.P. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography. Thromb. Res. 2001; 104: 467-74.
20. Duval C., Ali M., Chaudhry W.W. et al. Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):308-16. doi: 10.1161/ATVBAHA.115.306695.
21. Kapustin S.I. Hereditary thrombophilia as a polygenic pathology. Tromboz, Gemostaz i Reologia. 2006; 2 (26): 24-34.
22. Bray P.F. Integrin polymorphisms as risk factors for thrombosis. Thromb. Haemost. 1999; 82: 337- 44.
23. Verschuren J.J.W., Trompet S., Postmus I. Systematic Testing of Literature Reported Genetic Variation Associated with Coronary Restenosis: Results of the GENDER Study. PLoS One. 2012; 7(8): e42401. doi: 10.1371/journal.pone.0042401
24. Dashkova A.A., Chumakov G.A. The role of polymorphisms of some genes hemostasis systems and folate cycle in the occurrence of restenosis in patients with chronic coronary heart disease after coronary stenting. Vestnik Rossijskogo gosudarstvennogo meditsinskogo universiteta. 2012, 1:115-116.
